Climb Bio (NASDAQ:CLYM – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, Zacks reports.
Climb Bio Stock Down 0.8 %
Shares of Climb Bio stock traded down $0.01 during mid-day trading on Wednesday, reaching $1.29. 66,666 shares of the stock traded hands, compared to its average volume of 374,272. The stock has a market capitalization of $86.72 million, a PE ratio of -0.61 and a beta of -0.19. The company has a 50-day moving average price of $1.59. Climb Bio has a fifty-two week low of $1.20 and a fifty-two week high of $11.55.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on CLYM. Leerink Partnrs upgraded Climb Bio to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Climb Bio in a report on Monday, December 2nd. They set an “outperform” rating and a $10.00 price objective on the stock.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Read More
- Five stocks we like better than Climb Bio
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Energy Transfer: Powering Data With Dividends and Diversification
- Expert Stock Trading Psychology Tips
- Qualcomm Stock Is Coiling for a Breakout
- What is MarketRank™? How to Use it
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
